Drugs / CoV2-OGEN1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04893512 | Jun 2021 → Nov 2022 | COVID-19 | Syneos Health | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CoV2-OGEN1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04893512 ↗ |
| Modality | Vaccine | “safety of 2 dose vaccination schedule of orally administered CoV2-OGEN1 In healthy subjects” NCT04893512 ↗ |
| Route | Oral | “administered oral doses of 50mcg, 100mcg and 200mcg CoV2-OGEN1” NCT04893512 ↗ |